Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Silence Therapeutics Analyst Ratings and Price Targets | NASDAQ:SLN | Benzinga
Silence Therapeutics PLC has a consensus price target of $37 based on the ratings of 6 analysts. The high is $75 issued by HC Wainwright & Co. on March 7, 2025. The low is $4 issued by Goldman Sachs on March 4, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Morgan Stanley, and BMO Capital on March 7, 2025, March 5, 2025, and March 4, 2025, respectively. With an average price target of $48.33 between HC Wainwright & Co., Morgan Stanley, and BMO Capital, there's an implied 1253.87% upside for Silence Therapeutics PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Morgan Stanley
BMO Capital
Goldman Sachs
Chardan Capital
1calculated from analyst ratings
Analyst Ratings for Silence Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2025 | Buy Now | 1160.5% | Morgan Stanley | Michael Ulz57% | $49 → $45 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | 600.28% | BMO Capital | Kostas Biliouris34% | $67 → $25 | Maintains | Outperform | Get Alert |
| 03/04/2025 | Buy Now | 12.04% | Goldman Sachs | Richard Law67% | $6 → $4 | Maintains | Sell | Get Alert |
| 02/11/2025 | Buy Now | 68.07% | Goldman Sachs | Richard Law67% | → $6 | Initiates | → Sell | Get Alert |
| 02/03/2025 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 1440.62% | Chardan Capital | Keay Nakae58% | $55 → $55 | Maintains | Buy | Get Alert |
| 12/09/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 1440.62% | Chardan Capital | Keay Nakae58% | $55 → $55 | Maintains | Buy | Get Alert |
| 10/08/2024 | Buy Now | 1272.55% | Morgan Stanley | Michael Ulz57% | $49 → $49 | Reiterates | Overweight → Overweight | Get Alert |
| 08/30/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 1440.62% | Chardan Capital | Keay Nakae58% | $55 → $55 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 1272.55% | Morgan Stanley | Michael Ulz57% | $45 → $49 | Maintains | Overweight | Get Alert |
| 06/28/2024 | Buy Now | 1440.62% | Chardan Capital | Keay Nakae58% | $42 → $55 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 1076.47% | Chardan Capital | Keay Nakae58% | $42 → $42 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 1160.5% | Morgan Stanley | Michael Ulz57% | $45 → $45 | Maintains | Overweight | Get Alert |
| 03/15/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 1160.5% | Morgan Stanley | Michael Ulz57% | $29 → $45 | Maintains | Overweight | Get Alert |
| 03/14/2024 | Buy Now | 1076.47% | Chardan Capital | Keay Nakae58% | $26 → $42 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | Buy Now | 1776.75% | BMO Capital | Kostas Biliouris34% | → $67 | Initiates | → Outperform | Get Alert |
| 01/18/2024 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 11/17/2023 | Buy Now | 2000.84% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $75 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 2140.9% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | Buy Now | 628.29% | Chardan Capital | Keay Nakae58% | → $26 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 460.22% | Morgan Stanley | Michael Ulz57% | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 07/17/2023 | Buy Now | 460.22% | Morgan Stanley | Michael Ulz57% | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2023 | Buy Now | 460.22% | Morgan Stanley | Michael Ulz57% | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2023 | Buy Now | 460.22% | Morgan Stanley | Michael Ulz57% | → $20 | Reiterates | → Overweight | Get Alert |
| 06/12/2023 | Buy Now | 460.22% | Morgan Stanley | Michael Ulz57% | → $20 | Reiterates | → Overweight | Get Alert |
| 05/18/2023 | Buy Now | 2140.9% | HC Wainwright & Co. | Patrick Trucchio47% | → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 2140.9% | HC Wainwright & Co. | Patrick Trucchio47% | → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2023 | Buy Now | 460.22% | Morgan Stanley | Michael Ulz57% | → $20 | Initiates | → Overweight | Get Alert |
| 03/17/2023 | Buy Now | 2140.9% | HC Wainwright & Co. | Patrick Trucchio47% | → $80 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | 628.29% | Chardan Capital | Keay Nakae58% | $29 → $26 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | 404.2% | Morgan Stanley | Andrew Galler32% | → $18 | Initiates | → Equal-Weight | Get Alert |
| 12/06/2022 | Buy Now | 2140.9% | HC Wainwright & Co. | Patrick Trucchio47% | $95 → $80 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 712.32% | Chardan Capital | Keay Nakae58% | $33 → $29 | Maintains | Buy | Get Alert |
| 03/31/2022 | Buy Now | 824.37% | Chardan Capital | Keay Nakae58% | → $33 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Silence Therapeutics (SLN) stock?
The latest price target for Silence Therapeutics (NASDAQ:SLN) was reported by HC Wainwright & Co. on March 7, 2025. The analyst firm set a price target for $75.00 expecting SLN to rise to within 12 months (a possible 2000.84% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Silence Therapeutics (SLN)?
The latest analyst rating for Silence Therapeutics (NASDAQ:SLN) was provided by HC Wainwright & Co., and Silence Therapeutics reiterated their buy rating.
When was the last upgrade for Silence Therapeutics (SLN)?
There is no last upgrade for Silence Therapeutics
When was the last downgrade for Silence Therapeutics (SLN)?
There is no last downgrade for Silence Therapeutics.
When is the next analyst rating going to be posted or updated for Silence Therapeutics (SLN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Silence Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Silence Therapeutics was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating Silence Therapeutics (SLN) correct?
While ratings are subjective and will change, the latest Silence Therapeutics (SLN) rating was a reiterated with a price target of $75.00 to $75.00. The current price Silence Therapeutics (SLN) is trading at is $3.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.